BioSight
Companies
Voyager Therapeutics, Inc. logo

VYGR

NASDAQLEXINGTON, MA
Voyager Therapeutics, Inc.

Voyager Therapeutics develops gene therapies, antibody treatments, and small molecule drugs, primarily using adeno-associated virus (AAV) technology and a blood-brain-barrier shuttle platform called NeuroShuttle to target neurological diseases. The company has multiple programs in early-stage development, with a Phase 1 trial of VY7523 for early Alzheimer's disease expected to generate initial data in the second half of 2026, and maintains strategic partnerships with Neurocrine Biosciences and Novartis to fund and advance its pipeline.

Price history not yet available for VYGR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar